Press

Mindset Pharma Further Expands its IP Portfolio with Three Additional Non-Tryptamine Families of Next-Generation Psychedelic Compounds

Aug 31 • 3 min read

Mindset Pharma, Inc (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that through its discovery work, it has identified three additional families of highly novel, non-tryptamine, next-generation…

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 31 • 2 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) is pleased to announce that it has closed its previously announced overnight marketed offering of 2,858,000 units of the Company at a price of $1.40 per Unit for gross proceeds of approximately $4 million. Each Unit is comprised of one common share in the capital of the Company…

Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board

Aug 30 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, today announce the appointment of Najla Guthrie to the Benzinga Psychedelic Advisory Council. The Benzinga Psychedelics Advisory Council is a…

Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences

Aug 30 • 3 min read

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two upcoming psychedelic conferences: Jefferies Innovation in Mental Health Summit, Psychedelics and New Emerging Treatments, September 22nd in New York City, NY Cantor Neurology and Psychiatry Conference, October 6th in San Francisco, CA…

Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center

Aug 30 • 5 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a Canadian-based company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms for transformational human experiences, is pleased to announce that it has entered into its first international psilocybin supply agreement with Promises Innovative Recovery (“PIR”). Through founders Pamela and Gary Roberts,…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435